AMGEN INC
AMGEN INC (AMGN): 60 pipeline candidates · 35 upcoming catalysts · ~16 mo cash runway · 96 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.1 months
1% dilution
Lead: Phase 3
60 candidates
35 upcoming, next in ~4d
0 buys · 4 sells (180d)
A transparent, data-derived signal for AMGEN INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$191.7B
Cash
$12.0B
Quarterly Burn
$3.3B
Runway
16.1 mo
Revenue
$8.6B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (60 candidates)
| Drug | Phase |
|---|---|
| AB248 | Phase 1 |
| abiraterone | Phase 1 |
| abp 206 | Phase 3 |
| abp 234 | Phase 3 |
| abp 692 | Phase 3 |
| abp 938 | Phase 3 |
| amg 127 | Phase 1 |
| amg 133 | Phase 1 |
| amg 355 | Phase 1 |
| amg 378 | Phase 1 |
Showing 10 of 60 candidates. Sign up for full pipeline.
Upcoming Catalysts (35)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3,114
Total value held
$149.82B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 70,028,464 | $24.64B |
| blackrock, inc. | 47,100,472 | $16.57B |
| state street corp | 30,548,488 | $10.75B |
| morgan stanley | 15,836,058 | $5.57B |
| geode capital management, llc | 15,430,524 | $5.41B |
| vanguard portfolio management llc | 14,621,148 | $5.14B |
| charles schwab investment management inc | 12,773,386 | $4.49B |
| primecap management co/ca/ | 8,874,129 | $3.12B |
| capital international investors | 7,122,275 | $2.51B |
| wells fargo & company/mn | 7,090,110 | $2.49B |
Showing top 10 of 3,114 institutional holders of AMGEN INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AMGEN INC's pipeline?
AMGEN INC (AMGN) has 60 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AMGEN INC's lead drug candidate?
AMGEN INC's most advanced tracked candidate is AB248 (Phase 1) for Extensive Stage Small Cell Lung Cancer.
What is AMGEN INC's next catalyst?
AMGEN INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and" — expected June 22, 2026.
What is AMGEN INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AMGEN INC has approximately 16.1 months of cash runway.
What is AMGEN INC's market capitalization?
AMGEN INC's market capitalization is approximately $191.7B.
Get the full picture on AMGEN INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.